Autopsy report · NCT02578511
Standard Maintenance POMP/D Plus Ixazomib Maintenance Therapy in Adult Patients With Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma or Mixed Phenotype Acute Leukemia in Complete Remission (CR)
Cause of deathSlow enrollment
“No enrollment, another competing study and difficult to find the right person to enroll on this study.”
Life of this trial
- Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.
Vital statistics
- Status
- Withdrawn
- Phase
- Phase 1
- Sponsor
- Ehab L Atallah
- Sponsor type
- University, hospital or other
- Conditions
- Acute Lymphoblastic Leukemia in Complete Remission; Lymphoblastic Lymphoma in Complete Remission; Mixed Phenotype Acute Leukemia in Complete Remission
- Interventions
- Ixazomib
- Participants
- 0
- Sites
- 1
- Countries
- United States
Trials that died the same way
- Study of Neoadjuvant Imprime PGG and Pembrolizumab for Stage III, Resectable Melanoma
“Enrollment challenges, study not feasible” - Platelet Function With New Pediatric Oxygenator and Heparin and Non Heparin Coating in Pediatric Cardiac Surgery
“for difficulty to enroll patients in the study” - H-29 DELTA Multihole TT Study.
“Lack of progress in fulfilling the Study activities, including the lack of enrollment of participants” - Body Composition and Lifestyle Factors in ROTC
“The study did not enroll participants” - Hematopoietic Stem Cell Therapy for Patients With Refractory Myasthenia Gravis
“No participants enrolled for more than two years. No plan to continue study.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.